NCT00047060 2023-11-14
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
Clinical Trials
18 trialsNCT01030900 2022-10-06
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00061945 2022-05-03
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02689453 2022-04-29
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00069238 2022-02-24
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00520130 2019-03-05
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00262925 2015-05-05
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00098670 2014-05-21
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00274976 2013-11-06
Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00363090 2013-09-20
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00562068 2013-08-26
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00458523 2013-08-12
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
National Cancer Institute (NCI)
Phase 2 Completed
NCT00086775 2013-08-02
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00720447 2013-08-02
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00907036 2013-08-02
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00908180 2013-08-02
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00089349 2013-06-05
Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00061048 2012-10-31
Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed